SCD and prostate carcinoma: In vivo mouse xenograft models illustrated that tumor growth is impeded by Scd1 shRNA knockdown and Scd1 pharmacological inhibition in renal cell carcinoma, endometrial cancer, glioblastoma, and prostate cancer [56,59,60,61].